Scientific exchange · Dr. Noor Abbott

07 Jan 2026 · Phone · Dr. Noor Abbott, Hospital Clínic Barcelona · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0054—

Topics discussed

What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?
What was the median PD-L1 testing turnaround in the pivotal trial sites?

Scientific exchange with oncology pharmacist at Hospital Clínic Barcelona. Discussed brain-metastasis subgroup data.

INS-0053High
Brain-metastasis subgroup data
Brain-metastasis subgroup data: gap in current materials reported by oncology pharmacist (ES).
Archived

Review complete. Quality ratings and insights can now be used in aggregates.

0 of 1 complete

1–5, rated at review

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
12 Sept 2026, 06:22 UTC	Create	RARachel Adeyemi	topics	— → In progress	—	UI